Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy-Reference-Cited by-同舟云学术

Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy

Published:2023-08-12 Issue:10 Volume:40 Page:4545-4560
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Hayashi Hidetoshi^ORCID,Nishio Makoto,Takahashi Michiko,Tsuchiya Hiroaki,Kasahara-Kiritani Mami^ORCID

Funder

Janssen Japan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02616-9.pdf

Reference34 articles.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.

2. The Editorial Board of Cancer Statistics in Japan. Cancer Statistics in Japan 2022. Tokyo: Foundation for Promotion of Cancer Research (FPCR); 2022. https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2022.pdf. Accessed 21 Apr 2023.

3. American Society of Clinical Oncology (ASCO). Lung cancer: Non-small cell: Statistics. Alexandria (VA): American Society of Clinical Oncology (ASCO); 2022. Available from: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Accessed 21 Apr 2023.

4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med. 2002;346:92–8.

5. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5:2892–911.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?;CLIN LUNG CANCER;2024

2. Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?;Clinical Lung Cancer;2024-09

3. Speeding up Antibody-Drug Conjugate Development in Pretreated EGFR-Mutant Non–Small-Cell Lung Cancer;Journal of Clinical Oncology;2023-12-10